Labcorp Holdings Inc. $LH Shares Purchased by Tidal Investments LLC

Tidal Investments LLC boosted its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 12.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 30,559 shares of the medical research company’s stock after purchasing an additional 3,372 shares during the period. Tidal Investments LLC’s holdings in Labcorp were worth $8,557,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System increased its holdings in shares of Labcorp by 28,952.8% during the 2nd quarter. California State Teachers Retirement System now owns 35,002,800 shares of the medical research company’s stock worth $9,800,784,000 after buying an additional 34,882,320 shares during the last quarter. Victory Capital Management Inc. grew its position in Labcorp by 103.1% during the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock valued at $1,343,922,000 after acquiring an additional 2,719,475 shares during the period. Allspring Global Investments Holdings LLC increased its stake in Labcorp by 1.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 2,226,446 shares of the medical research company’s stock worth $607,241,000 after acquiring an additional 22,170 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Labcorp by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,137,010 shares of the medical research company’s stock worth $534,023,000 after purchasing an additional 13,775 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Labcorp by 15.9% in the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock valued at $604,488,000 after purchasing an additional 289,029 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on LH. Piper Sandler increased their target price on shares of Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Truist Financial lifted their target price on shares of Labcorp from $320.00 to $350.00 and gave the company a “buy” rating in a report on Friday, July 31st. Morgan Stanley increased their price target on Labcorp from $308.00 to $338.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Mizuho set a $355.00 price objective on Labcorp in a research report on Monday, August 10th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $336.36.

Labcorp Stock Up 1.4%

NYSE LH opened at $311.36 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. Labcorp Holdings Inc. has a fifty-two week low of $244.52 and a fifty-two week high of $341.80. The business has a 50 day moving average price of $310.39 and a two-hundred day moving average price of $281.94. The stock has a market cap of $25.25 billion, a PE ratio of 25.75, a P/E/G ratio of 1.77 and a beta of 0.88.

Labcorp (NYSE:LH) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same quarter last year, the firm posted $4.35 earnings per share. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, sell-side analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 28th were paid a dividend of $0.72 per share. The ex-dividend date of this dividend was Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 0.9%. Labcorp’s payout ratio is 23.82%.

Labcorp News Summary

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reaffirmed its 2026 guidance of adjusted EPS of $18.10 to $18.55, broadly consistent with the analyst consensus of $18.32. Maintaining guidance supports confidence in near-term earnings visibility. Labcorp Holdings Reiterates 2026 Outlook, Issues Long-Term Guidance
• Positive Sentiment: The company issued a 2029 outlook calling for compound annual revenue growth of 5% to 8% and adjusted EPS growth of 8.5% to 11.5%. The targets imply sustained expansion beyond the current year and could support a higher long-term earnings outlook. Labcorp 2026 Investor Day Announcement
• Positive Sentiment: Labcorp plans to use artificial intelligence, specialty testing, scientific capabilities and global scale to drive growth. Management also emphasized strong cash-flow generation and disciplined capital deployment, which may improve shareholder returns if execution meets expectations. Labcorp Bets Big on AI and Specialty Testing
• Neutral Sentiment: The Investor Day transcript provided additional detail on Labcorp’s strategic priorities and long-term financial framework, but the benefits depend on successful implementation and investment in new technologies and testing capabilities. Labcorp Analyst and Investor Day Transcript
• Negative Sentiment: LH recently declined about 4.3% and underperformed peers, indicating that investors may have viewed the Investor Day information as insufficient to justify the stock’s elevated valuation or may have taken profits despite the favorable long-term targets. Labcorp Stock Heads Into the Open After a 4.3 Percent Slide

Insider Activity

In other news, EVP Kathryn W. Kyle sold 92 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the completion of the sale, the executive vice president directly owned 3,904 shares in the company, valued at $1,117,285.76. This trade represents a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kerrii B. Anderson sold 3,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the completion of the transaction, the director owned 6,563 shares in the company, valued at approximately $2,087,165.26. This trade represents a 31.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,919 shares of company stock worth $2,826,593 over the last three months. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Profile

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.